The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2025 | Phase Ib trial of ivosidenib plus ruxolitinib in IDH1-mutated advanced MPNs
Anand Patel, MD, University of Chicago Medical Center, Chicago, IL, discusses a Phase Ib trial (NCT06291987) investigating the combination of ivosidenib and ruxolitinib in patients with IDH1-mutated advanced myeloproliferative neoplasms (MPNs), highlighting the need for targeted therapy approaches in this setting. Dr Patel explains that the trial aims to determine the safety of combining these two agents and will also assess efficacy response, survival outcomes, and molecular mutations that may influence response or relapse. This interview took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
